IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1)
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Cytokines play important roles in tumorigenesis and progression of cancer cells, while their functions in drug resistance remain to be illustrated. We successfully generated doxorubicin (Dox)-resistant CRC HCT-116 and SW480 cells (namely HCT-116/Dox and SW480/Dox, respectively). Cytokine expression analysis revealed that IL-8, while not FGF-2, EGF, TGF-β, IL-6, or IL-10, was significantly increased in Dox-resistant CRC cells as compared with their corresponding parental cells. Targeted inhibition of IL-8 via siRNAs or its inhibitor reparixin can increase the Dox sensitivity of HCT-116/Dox and SW480/Dox cells. The si-IL-8 can decrease the mRNA and protein expression of multidrug resistance 1 (MDR1, encoded by ABCB1), while has no effect on the expression of multidrug resistance-associated protein 1 (ABCC1), in CRC Dox-resistant cells. IL-8 can increase the phosphorylation of p65 and then upregulate the binding between p65 and promoter of ABCB1. BAY 11-7082, the inhibitor of NF-κB, suppressed the recombination IL-8 (rIL-8) induced upregulation of ABCB1. It confirmed that NF-κB is involved in IL-8-induced upregulation of ABCB1. rIL-8 also increased the phosphorylation of IKK-β, which can further activate NF-κB, while specific inhibitor of IKK-β (ACHP) can reverse rIL-8-induced phosphorylation of p65 and upregulation of MDR1. These results suggested that IL-8 regulates the Dox resistance of CRC cells via modulation of MDR1 through IKK-β/p65 signals. The targeted inhibition of IL-8 might be an important potential approach to overcome the clinical Dox resistance in CRC patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, P-gp is overexpressed in CRC cell lines and specimens resistant to 5-FU/Dox/oxaliplatin [31,117,118].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [118]
Citations
Cites
1 retracted
Xi, G., Hayes, E., Lewis, R., Ichi, S., Mania-Farnell, B. L., Shim, K., Takao, T., Allender, E., Mayanil, C. S. K., & Tomita, T. (2015) · Oncogene · doi:10.1038/onc.2015.78 · Cited by 67
RetractedMultidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Huang, D., Ding, Y., Zhou, M., Rini, B. I., Petillo, D., Qian, C.-N., Kahnoski, R., Futreal, P. A., Furge, K. A., & Teh, B. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3965 · Cited by 417
De Larco, J. E., Wuertz, B. R. K., & Furcht, L. T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0760 · Cited by 412
Ning, Y., Manegold, P. C., Hong, Y. K., Zhang, W., Pohl, A., Lurje, G., Winder, T., Yang, D., LaBonte, M. J., Wilson, P. M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25562 · Cited by 406
Transcriptional regulation of ABC drug transporters
Scotto, K. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206950 · Cited by 392
Cited by
Fousek, K., Horn, L. A., & Palena, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107692 · Cited by 359
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 334
Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein (Review)
Tian, Y., Lei, Y., Wang, Y., Lai, J., Wang, J., & Xia, F. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5567 · Cited by 197
“Notably, NF‐κB (P65) may be activated by IL‐8 via upregulation of IKKβ phosphorylation, thus resulting in over‐ expression of P‐gp (49).”
BackgroundThe Role of Interleukins in Colorectal Cancer
Li, J., Huang, L., Zhao, H., Yan, Y., & Lü, J. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.46651 · Cited by 163
“IL-8 participates in most phases of tumour development from cell proliferation and angiogenesis to cancer metastasis, moreover, some evidence has shown that IL-8 is associated with chemotherapeutic responses [91-93].”
BackgroundDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Self-citationTumour Cell Secretome in Chemoresistance and Tumour Recurrence
Madden, E. C., Gorman, A. M., Logue, S. E., & Samali, A. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.020 · Cited by 159
Guo, Y., Ashrafizadeh, M., Tambuwala, M. M., Ren, J., Orive, G., & Yu, G. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104161 · Cited by 85
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 74
Bazzichetto, C., Milella, M., Zampiva, I., Simionato, F., Amoreo, C. A., Buglioni, S., Pacelli, C., Pera, L. L., Colombo, T., Bria, E., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102631 · Cited by 69
“Doxorubicin-resistant CRC cells, compared to doxorubicin-sensitive ones, display higher levels of IL-8, and IL-8 silencing restores chemosensitivity by downregulating the expression of multidrug resistance 1 (Figure 1C) [25].”
BackgroundComprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
Oh, J. M., Kim, S. W., Tsung, C., Kent, E. W., Jain, A., Ruff, S. M., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571731 · Cited by 56
Alkaraki, A., Alshaer, W., Wehaibi, S., Gharaibeh, L. F., Abuarqoub, D. A., Alqudah, D. A., Al-Azzawi, H., Zureigat, H., SOULEIMAN, M. M., & Awidi, A. (2020) · Breast Cancer · doi:10.1007/s12282-020-01098-9 · Cited by 50
Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery
Simpson, S., Rizvanov, A. A., Jeyapalan, J. N., de Brot, S., & Rutland, C. S. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.965391 · Cited by 43
Gong, B., Kao, Y., Zhang, C., Sun, F., Gong, Z., & Chen, J. (2020) · Mediators of Inflammation · doi:10.1155/2020/5934821 · Cited by 41
“However, high expression of CXCL8 could act as a protective barrier for liver metastasis of CRC and coincide with better prognosis [46, 47].”
BackgroundAlbadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 38
The Mechanistic Roles of ncRNAs in Promoting and Supporting Chemoresistance of Colorectal Cancer
Micallef, I., & Baron, B. (2021) · Non-Coding RNA · doi:10.3390/ncrna7020024 · Cited by 32
Fusobacterium nucleatum modulates the Wnt/β-catenin pathway in colorectal cancer development
Mondal, T., Chattopadhyay, D., Mondal, P. S., Das, S., Mondal, A., Das, A., Samanta, S., & Saha, T. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140196 · Cited by 32
McClelland, S., Maxwell, P. J., Branco, C. M., Barry, S. T., Eberlein, C., & LaBonte, M. J. (2024) · Cancers · doi:10.3390/cancers16162797 · Cited by 30
“IL-8 attracts these immune cells, which can dampen the immune response and allow tumour cells to persist and progress [79].”
BackgroundChiu, K.-J., Chiou, H.-Y. C., Huang, C.-H., Lu, P.-C., Kuo, H.-R., Wang, J., & Lin, M. (2022) · Biomedicines · doi:10.3390/biomedicines10030713 · Cited by 29
“Similarly, interleukin-8 (IL-8) is demonstrated to modulate doxycycline [53] and cisplatin [54] resistance via the nuclear factor-kappa B (NF-κB) signaling pathway.”
BackgroundCui, G., Wang, Z., Liu, H., & Pang, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1057181 · Cited by 28
Bohne, A., Grundler, E., Knüttel, H., Völkel, V., & Fürst, A. (2023) · Surgical Endoscopy · doi:10.1007/s00464-023-10582-0 · Cited by 27
“…generally play a crucial role in CRC [72]: IL-6 facilitates angiogenesis, migration and proliferation [73, 74]; high serum IL-8 contributes to growth and progression of CRC [75] and is even associated with resistance to chemotherapy, an important pillar of CRC treatment besides surgery [76–78].”
Cheng, M., Cai, W., Huang, W., Chen, Y. X., Wu, Z., Luo, P., & Yan, W. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.09.032 · Cited by 25
Self-citationRen, S.-N., Zhang, Z.-Y., Guo, R.-J., Wang, D., Chen, F., Chen, X., & Fang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1911 · Cited by 22
Joshi, S., Pandey, R., Kumar, A., Gupta, V. K., & Arya, N. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156155 · Cited by 22
Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance
Han, J., Liang, W., & Li, K. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1753180 · Cited by 21
Wu, M., Zhang, X., Zhang, W., Yan, L., Liu, X., Zhang, M., Pan, Y., Lobie, P. E., Han, X., & Zhu, T. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01068-6 · Cited by 21
Gao, Z., Li, Z., Liu, Y., & Liu, Z. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.554 · Cited by 21
“Moreover, many studies proved that there was positive relationship between MDR1 and the resistance to various drugs in CC treatment, such as doxorubicin (Du et al., 2018; Yan, Zhao, & Zhang, 2017), oxaliplatin (Zhou et al.”
BackgroundHuang, T., Mokgautsi, N., Huang, Y., Wu, A. T. H., & Huang, H. (2021) · Cells · doi:10.3390/cells10081970 · Cited by 20
“In addition, recent reports gradually showed that an increased level of CXCL8 mediates tumor metastasis, stemness, and ultimately induces chemoresistance in CRC [31,32].”
BackgroundQiu, H., Gu, X. Q., Chen, X., Song, W., Wang, A., & Chu, J. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108158 · Cited by 20
Yati, S., Silathapanasakul, A., Thakaeng, C., Chanasakulniyom, M., Songtawee, N., Porntadavity, S., Pothacharoen, P., Pruksakorn, D., Kongtawelert, P., Yenchitsomanus, P., et al. (2022) · Cells · doi:10.3390/cells11061042 · Cited by 19
Barillé‐Nion, S., Lohard, S., & Juin, P. P. (2020) · Biomolecules · doi:10.3390/biom10081109 · Cited by 18
Protein post-translational modifications: A key factor in colorectal cancer resistance mechanisms
Bi, B., Qiu, M., Liu, P. F., Wang, Q., Wen, Y., Li, Y., Li, B., Li, Y., He, Y., & Zhao, J. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.194977 · Cited by 19
Self-citationWang, R., Fang, P., Chen, X., Ji, J., Yu, D., Mei, F., Wang, Z., Zhou, W., Peng, W., Wang, R., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102213 · Cited by 17
Small Interfering RNA in Colorectal Cancer Liver Metastasis Therapy
Xie, J., & Wang, S. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221103318 · Cited by 16
A comprehensive update on the potential of curcumin to enhance chemosensitivity in colorectal cancer
Shadnoush, M., Momenan, M., Seidel, V., Tierling, S., Fatemi, N., Mojarad, E. N., Norooz, M. T., & Cheraghpour, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00652-y · Cited by 14
“Du and colleagues demonstrated that interleukin-8 activates the NF-κ B signaling pathway, thereby stimulating MDR1 expression, which induces resistance to DOX [36].”
Lin, H.-Y., Wang, W.-K., Lin, C.-H., Kuei, C., Lee, H., Lin, Y.-H. K., Chiu, H., & Lin, Y. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.06.049 · Cited by 14
Liu, T., Cui, L., He, Z., Chen, Z., Tao, H., & Yang, J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288492 · Cited by 13
“A few studies demonstrated that the expression of IL-6, IL-8, and IL-1β could promote the tumor relapse and metastasis [35,36].”
BackgroundPotential roles of brain barrier dysfunctions in the early stage of Alzheimer’s disease
Jian, W., Zhang, Z., Chu, S., Peng, Y., & Chen, N. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.08.012 · Cited by 11
Identification of intestinal flora-related key genes and therapeutic drugs in colorectal cancer
Zhang, J., Zhang, H., Li, F., Song, Z., Li, Y., & Zhao, T. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-00810-0 · Cited by 9
Gao, M., Liu, L., Zhang, X., Li, Z., & Zhang, M. (2021) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2021.103639 · Cited by 9
Li, S., Xie, M., Du, Y., & Tan, Z. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02235-7 · Cited by 7
“4) [150].”
InfluentialPreparation and pH/temperature dual drug release behavior of polyamino acid nanomicelles
Hu, Z., Guo, Z., Han, S., Chen, Z., Wang, J., Hu, J., & Reheman, A. (2021) · Polymer Bulletin · doi:10.1007/s00289-021-03735-5 · Cited by 7
Moatar, A. E. (2020) · FARMACIA · doi:10.31925/farmacia.2020.4.17 · Cited by 6
“Indeed, in tumours and metastases, IL-8 promotes T cell infiltration, tumourigenesis, angiogenesis and chemoresistance [12].”
The lncrnas: innovative multifunctional players of drug resistance in colorectal cancer
Maghsoudi, H., Rasoulzadeh, M., Abbastabar, M., Fazilat, A., Sheikhnia, F., Azizzadeh, B., Valilo, M., & Majidinia, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03951-3 · Cited by 5
Röhl, L., Wellhausen, J., Berszin, M., Krücken, I., Zebralla, V., Pirlich, M., Wiegand, S., Dietz, A., Wald, T., & Wichmann, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1237623 · Cited by 5
Nutrients Lowering Obesity-Linked Chemokines Blamable for Metastasis
Ion, G., Bostan, M., Hardman, W. E., McFarland, M. P., Bleoţu, C., Radu, N., Diaconu, C. C., Mihaila, M. A., Caramihai, M. D., & Hotnog, C. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052275 · Cited by 4
“Thus, it regulates resistance to cetuximab through the activation of the EGFR pathway [209] and doxorubicin by the modulation of multidrug resistance 1 (MDR1) via inhibitor of nuclear factor kappa-B kinase subunit beta 1 (IKK-β /p65) [210].”
Fan, Y.-W., Liu, Y.-X., Jiang, N.-J., Qian, S., Huang, X., Wu, J., & He, M. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103185 · Cited by 4
Sritharan, S., & Sivalingam, N. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03380-6 · Cited by 4
“In another study, IL-8-mediated up-regulation of MDR1 has been noted in dox-resistant colon cancer cell lines, HCT-116/Dox and SW480/ Dox [34].”
Федотчева, Т. А., & Shimanovsky, N. L. (2023) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-023-02864-7 · Cited by 2
Федотчева, Т. А., & Шимановский, Н. Л. (2023) · Химико-фармацевтический журнал · doi:10.30906/0023-1134-2023-57-2-3-11
McCusker, S. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.240009
Hammood, A. R. R. Z. Y. (2025) · International Journal of Environmental Sciences · doi:10.64252/swp0s472
Wu, M., Zhang, X., Zhang, W., Yan, L., Liu, X., Zhang, M., Pan, Y., Lobie, P. E., Han, X., & Zhu, T. (2023) · Figshare · doi:10.6084/m9.figshare.22617262
Miroschnikov, N. (2024) · DuEPublico (University of Duisburg-Essen) · doi:10.17185/duepublico/78111
Wu, M., Zhang, X., Zhang, W., Yan, L., Liu, X., Zhang, M., Pan, Y., Lobie, P. E., Han, X., & Zhu, T. (2023) · Figshare · doi:10.6084/m9.figshare.22617259
The effect of lncRNA UCA1 on PI3K/AKT/mTOR signaling in doxorubicin-resistant ER+ breast cancer
Namalir, G. (2025) · Hitit University Institutional Repository
Godel, M. (n.d.) · Institutional Research Information System University of Turin (University of Turin)
BindingDB Entry 50007844: Natural products as multidrug resistance modulators in cancer.
BindingDB (2021) · UC San Diego · doi:10.7270/q2b27zmq
Röhl, L., Wellhausen, J., Berszin, M., Krücken, I., Zebralla, V., Pirlich, M., Wiegand, S., Dietz, A., Wald, T., & Wichmann, G. (2023) · doi:10.3389/fimmu.2023.1237623.s001
Metadata
- Authors
- Du, J., He, Y., Li, P., Wu, W., Chen, Y., & Ruan, H.
- Affiliations
- Zhejiang Provincial People's Hospital (CN)
- Nanchang University (CN)
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2018-04-24
- Volume
- 81
- Issue
- 6
- Pages
- 1111-1119
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2799985672
- Cited by
- 52
- References
- 34
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 5 · 2023: 14 · 2022: 7 · 2021: 4 · 2020: 8 · 2019: 3 · 2018: 2
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- the Natural Science Foundation of Zhejiang Province (LQ17H160016)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- interleukin-8, doxorubicin resistance, colorectal cancer, multidrug resistance 1, P-glycoprotein, NF-κB signaling, IKKβ, p65 phosphorylation, cytokines, reparixin, chemoresistance
- MeSH terms
- Antibiotics, Antineoplastic, Doxorubicin, Humans, Nitriles, Phosphorylation, Sulfonamides, Sulfones, Colorectal Neoplasms, Up-Regulation, Gene Expression Regulation, Neoplastic, Cytokines, Interleukin-8, NF-kappa B, ATP Binding Cassette Transporter, Subfamily B, Drug Resistance, Neoplasm, RNA, Small Interfering, HCT116 Cells, Cell Line, Tumor, I-kappa B Kinase, Transcription Factor RelA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.